TCL Archive Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase December 31, 2010
TCL Archive NCI to Press FDA For Quicker Drug Approval, Relaxation Of Survival Impact Requirement June 26, 1987